Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1216384 | 0.98 | ALOX15 (0.57) | ALOX15ALDH1A1ITGB3ITGA2BTRPV1 | |
| SCHEMBL1212294 | 0.96 | ALOX15 (0.57) | ALOX15ALDH1A1ITGB3ITGA2BTRPV1 | |
| SCHEMBL1213174 | 0.96 | ALOX15 (0.52) | ALOX15ALDH1A1ITGB3ITGA2BTRPV1 | |
| SCHEMBL1210494 | 0.95 | ALOX15 (0.53) | ALOX15ALDH1A1ITGB3ITGA2BTRPV1 | |
| SCHEMBL1213029 | 0.94 | ALOX15 (0.54) | ALOX15ALDH1A1ITGB3ITGA2BTRPV1 | |
| SCHEMBL1216127 | 0.94 | ALOX15 (0.49) | ALOX15ALDH1A1ITGB3ITGA2BTRPV1 | |
| SCHEMBL1212374 | 0.93 | ALOX15 (0.47) | ALOX15ALDH1A1ITGB3ITGA2BTRPV1 | |
| SCHEMBL1215863 | 0.93 | ALOX15 (0.58) | ALOX15ALDH1A1ITGB3ITGA2BTRPV1 | |
| SCHEMBL1214877 | 0.93 | ALOX15 (0.49) | ALOX15ALDH1A1ITGB3ITGA2BTRPV1 | |
| SCHEMBL1215552 | 0.93 | ALOX15 (0.51) | ALOX15ALDH1A1ITGB3ITGA2BTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028544-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7829592-B2 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2010-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028544-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | COMT, PARK7, DDT | ALOX15 513/4885ALDH1A1 636/4885ITGB3 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.